NCT00459836View on ClinicalTrials.gov

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

October 31, 2009

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

PR-104

DRUG

docetaxel

DRUG

gemcitabine hydrochloride

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Trial Locations (3)

2020

Waikato Hospital, Hamilton

92121

Proacta, Incorporated, San Diego

Unknown

University of Auckland Cancer Center, Auckland

All Listed Sponsors
lead

Proacta, Incorporated

INDUSTRY

NCT00459836 - PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors | Biotech Hunter | Biotech Hunter